Administration Proposes Rule to Expand Employer Coverage for IVF and Fertility Treatments

For millions of Americans, the path to parenthood is obstructed by a formidable financial barrier: the staggering cost of fertility treatments. A single cycle of in vitro fertilization (IVF) typically costs between $15,000 and $20,000, and many patients require multiple rounds to achieve a successful pregnancy. While most working-age adults receive health insurance through their employers, comprehensive fertility coverage remains a rarity. A primary reason for this gap isn't just cost aversion by employers, but a complex web of federal regulations that makes offering standalone fertility benefits legally perilous and administratively burdensome.[1][2]

To dismantle these regulatory hurdles, the Departments of Labor, Health and Human Services, and the Treasury have jointly proposed a rule that would fundamentally alter how employers can sponsor fertility care. The proposal seeks to classify fertility treatments as a "limited excepted benefit." In practice, this would allow companies to offer fertility coverage as a standalone policy—much like dental or vision insurance—entirely separate from their primary major medical plans. By decoupling fertility care from standard health insurance, the administration hopes to incentivize a massive expansion of employer-sponsored family-building benefits.[2][4]

The public comment period for the proposed rule officially closed on July 13, 2026, marking a critical milestone toward finalization. If adopted as drafted, the new regulatory framework would take effect for plan years beginning on or after January 1, 2027. Benefits experts and human resources professionals are already analyzing the proposal, which promises to give organizations significantly more flexibility in designing family-building benefits without triggering a cascade of federal compliance mandates. The timeline gives employers the remainder of the year to adjust their benefit architectures ahead of the 2027 open enrollment cycles.[4][5]

Understanding the significance of the rule requires a look at the current legal landscape. Under the Affordable Care Act (ACA) and the Health Insurance Portability and Accountability Act (HIPAA), group health plans are subject to strict market reforms, including prohibitions on annual dollar limits and requirements to cover specific preventive services without cost-sharing. If an employer attempts to offer a specialized "carve-out" plan solely for fertility treatments, that standalone plan typically fails to meet these comprehensive ACA requirements, exposing the employer to severe financial penalties and compliance liabilities.[5]

By designating fertility benefits as "excepted benefits," the administration provides a legal safe harbor. Excepted benefits are statutorily exempt from the ACA's broader market reforms and many HIPAA portability rules. Under the proposed framework, employees would be able to enroll in the standalone fertility benefit even if they decline the employer's primary health insurance. This offers a flexible lifeline to workers who might otherwise rely on a spouse's plan that lacks IVF coverage, ensuring that access to fertility care is not contingent on enrolling in a specific major medical policy.[4][5]

The scope of the proposed coverage is intentionally broad. To qualify as an excepted benefit, the plan must dedicate "substantially all" of its benefits to the diagnosis, mitigation, or treatment of infertility and related reproductive health conditions. This encompasses a wide array of services, including diagnostic lab tests, hormone panels, intrauterine insemination (IUI), IVF procedures, fertility medications, and surgical treatments for underlying conditions like endometriosis or polycystic ovary syndrome (PCOS). The comprehensive definition ensures that patients receive support from initial diagnosis through advanced assisted reproductive technologies.[1][5]

To ensure the benefit provides meaningful financial relief, the proposed rule establishes a generous ceiling. The standalone plans would be permitted to offer a combined lifetime maximum benefit of up to $120,000 per participant, which includes coverage for eligible beneficiaries. Recognizing the escalating costs of medical care, the administration has stipulated that this $120,000 cap will be indexed for medical inflation for plan years beginning after December 31, 2027. This indexing mechanism is designed to prevent the benefit's purchasing power from eroding over time as clinical costs inevitably rise.[2][5]

Industry advocates have praised the $120,000 threshold as highly practical. Given the $15,000 to $20,000 average cost of a single IVF cycle, a six-figure lifetime cap provides enough runway for patients to undergo the multiple rounds of retrieval and transfer that are often medically necessary to achieve a live birth. It also leaves room to cover the exorbitant costs of specialized fertility medications, which can easily exceed $5,000 per cycle on their own, removing one of the most significant financial barriers to sustained treatment.[1][3]

The rulemaking is the centerpiece of a broader maternal health and family-building initiative spearheaded by the Trump administration. It builds directly upon an executive order signed by President Donald Trump in February 2025, which directed federal agencies to identify regulatory pathways to protect IVF access and drastically reduce out-of-pocket costs. The administration has framed the expansion of fertility benefits as both a pro-family policy and an economic imperative, aiming to support working parents while addressing long-term demographic shifts in the United States.[2][3]

Administration officials have explicitly linked the policy to demographic concerns. During the announcement of the rule, Health and Human Services Secretary Robert F. Kennedy Jr. characterized the ongoing decline in U.S. birth rates as a serious national challenge, arguing that the rule provides Americans with a tangible path to starting and growing their families. The initiative also dovetails with the administration's "TrumpRx" program, which recently secured a pricing agreement with pharmaceutical manufacturer EMD Serono to offer steep discounts on vital IVF medications like Gonal-f, further driving down the aggregate cost of care.[1][3]

For large employers, the rule offers a strategic workaround to the patchwork of state-level fertility mandates. Currently, 25 states and the District of Columbia require some form of private insurance coverage for fertility care. However, these state mandates generally do not apply to self-funded employer plans governed by the Employee Retirement Income Security Act (ERISA). The new federal pathway allows these large, self-funded employers to offer uniform, nationwide fertility benefits to their entire workforce without navigating conflicting state laws or compromising their ERISA exemptions.[5][6]

Despite the enthusiasm from family-building advocates, the proposed rule is not a federal mandate. Participation by employers remains entirely voluntary, meaning no company is forced to adopt the new excepted benefit. Benefits consultants caution that while the regulatory pathway will be cleared, companies must still weigh the financial costs of adding a new, potentially expensive benefit line against their overall compensation budgets. The immediate impact of the rule will depend heavily on corporate adoption rates and whether offering robust fertility coverage becomes a competitive necessity for talent retention in highly competitive labor markets.[4][6]

As the Departments of Labor, HHS, and Treasury review the public comments submitted through mid-July, the fertility industry is bracing for a potential surge in demand. If finalized, the rule could significantly expand the commercial market for specialty fertility benefit vendors and clinics. For now, advocates are urging patients not to delay time-sensitive treatments in anticipation of the rule, as the earliest these new employer-sponsored plans would become available is the beginning of 2027, and individual employer adoption timelines will vary widely.[1][5]